CYP19A1 and breast carcinoma: Furthermore, there are studies demonstrating a significant increment of STS and 17β-HSD1 following aromatase inhibitor therapy of ER positive postmenopausal breast carcinoma patients due to the compensatory response of breast carcinoma tissues to oestrogen depletion.12